Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, Fredrick B. Hagemeister et al.|The Lancet Oncology|2014Cited by 263
IgM myeloma: A multicenter retrospective study of 134 patientsJorge J. Castillo, Morie A. Gertz, Artur Jurczyszyn et al.|American Journal of Hematology|2017Cited by 49